TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

TCR2 Therapeutics

12/05/2022 13:03

* TCR2 Therapeutics Inc  TCRR.OQ  reported a quarterly
adjusted
loss of 76 cents​​ per share for the quarter ended in March. The
mean expectation of nine analysts for the quarter was for a loss
of 74 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * TCR2 Therapeutics Inc's reported EPS for the quarter was a
loss
of 76 cents​.
    * The mean earnings estimate of analysts had fallen by
about 0.7%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * TCR2 Therapeutics Inc shares had fallen by 21.4% this
quarter and lost 53.4% so far this year.
    * Wall Street's median 12-month price target for TCR2
Therapeutics
Inc is $19.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 12 at 12:03 p.m.  ​All
figures in US dollars unless otherwise stated